Source:http://linkedlifedata.com/resource/pubmed/id/11745451
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2001-12-17
|
| pubmed:abstractText |
Our aim was to assess the prognostic implications of the expression of p27(KIP1) and cyclin E in gastric lymphoma. We investigated the prognostic value of the immunoreactivity of these molecules in 92 cases of primary gastric lymphoma: 34 LGMLs, 24 DLCLMLs and 34 DLCLs. p27 was positive in 88% of LGMLs, 71% of DLCLMLs and 32% of DLCLs (p = 0.004); cyclin E was positive in 9%, 33% and 59% of cases, respectively (p < 0.00001). p27/cyclin E immunoreactivity significantly correlated with histologic category, stage and LDH serum level. p27 immunoreactivity was significantly associated with better survival, whereas cyclin E reactivity was significantly related to worse outcome. Five-year CSS was 94% for patients with p27(+)/cyclin E(-) phenotype (n = 42), 79% for p27(+)/cyclin E(+) (n = 14) or p27(-)/cyclin E(-) (n = 16) phenotype and 60% for p27(-)/cyclin E(+) phenotype (n = 16) (p = 0.02). The prognostic role of p27/cyclin E expression was confirmed when analyzed separately within LGMLs and large-cell lymphomas. Immunoreactivity for p27 and cyclin E is an independent predictor of survival in PGLs that may be an adjunctive tool in identifying high-risk patients. It correlates with histologic category, stage and LDH serum level. p27(-)/cyclin E(+) phenotype is associated with worse survival, probably due to a synergistic effect of both cell-cycle defects. The predictive role of these molecules within each histologic group of PGLs deserves to be confirmed in larger series.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin E,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/L-Lactate Dehydrogenase,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0020-7136
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2001 Wiley-Liss, Inc.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
94
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
599-604
|
| pubmed:dateRevised |
2007-7-24
|
| pubmed:meshHeading |
pubmed-meshheading:11745451-Adolescent,
pubmed-meshheading:11745451-Adult,
pubmed-meshheading:11745451-Age Factors,
pubmed-meshheading:11745451-Aged,
pubmed-meshheading:11745451-Aged, 80 and over,
pubmed-meshheading:11745451-Cell Cycle Proteins,
pubmed-meshheading:11745451-Cell Nucleus,
pubmed-meshheading:11745451-Cyclin E,
pubmed-meshheading:11745451-Cyclin-Dependent Kinase Inhibitor p27,
pubmed-meshheading:11745451-Female,
pubmed-meshheading:11745451-Humans,
pubmed-meshheading:11745451-Immunohistochemistry,
pubmed-meshheading:11745451-L-Lactate Dehydrogenase,
pubmed-meshheading:11745451-Lymphoma, Non-Hodgkin,
pubmed-meshheading:11745451-Male,
pubmed-meshheading:11745451-Middle Aged,
pubmed-meshheading:11745451-Multivariate Analysis,
pubmed-meshheading:11745451-Phenotype,
pubmed-meshheading:11745451-Prognosis,
pubmed-meshheading:11745451-Risk Factors,
pubmed-meshheading:11745451-Stomach Neoplasms,
pubmed-meshheading:11745451-Tumor Suppressor Proteins
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy. andres.ferreri@hsr.it
|
| pubmed:publicationType |
Journal Article
|